EVOCAL Health

EVOCAL Health operates at the intersection of digital diagnostics, vocal biomarkers, remote monitoring, and digital therapeutics. Its proposed differentiation is the use of voice, breathing, and coughing signals collected through everyday devices, potentially reducing dependence on specialized hardware and enabling lower-cost monitoring. The company also describes a broader infrastructure approach through its Vocal Biomarker Development Platform, Digital Diagnostics Platform, and Human Voice Project rather than a single disease-specific application. AliveCor is more closely associated with cardiac monitoring, while Empatica is known for wearable biosensing; EVOCAL Health’s stated focus is non-contact vocal and respiratory signals. Its Hamburg base, small employee band, and non-equity assistance financing indicate an early-stage position relative to larger diagnostic and monitoring companies. The principal strategic challenge is converting promising voice-based signals into clinically validated, regulated, and reimbursable products.

EVOCAL Health was founded in 2020 and appears to have progressed through an early research-and-platform-building phase. The first identified financing event occurred on Feb 25, 2021 through non-equity assistance associated with IFB Innovationsstarter. On Sep 27, 2021, the company announced its cloud-based Vocal Biomarker Development Platform, marking an inflection point from a broad mission around voice-based health detection toward a defined technical environment for development and data collection. A second non-equity assistance round on Oct 6, 2021 brought in PharmStars and Plug and Play Health and was followed by participation in PharmStars’ inaugural program. During 2022, EVOCAL Health expanded its public application narrative to cardiac rhythm management, remote patient monitoring, and digital therapeutics. Its product descriptions now cover respiratory, cardiovascular, and neurodegenerative use cases, suggesting an attempt to build a reusable biomarker platform rather than a single indication. Hiring signals cite software engineering, data science, medical writing, and marketing roles, indicating needs across technical, clinical-content, and commercialization functions. However, the company remains represented by a small employee band, and there is no disclosed funding amount, valuation, regulatory milestone, or post-2024 launch evidence to quantify growth.